Skip to main navigation Skip to search Skip to main content

Akt-2 Is a Potential Therapeutic Target for Disseminated Candidiasis

  • Ling Huang
  • , Yilei Ma
  • , Hui Guo
  • , Na Tang
  • , Song Ouyang
  • , Patrick Nuro-Gyina
  • , Lijian Tao
  • , Yusen Liu
  • , Matthew C. O'Brien
  • , Wallace Y. Langdon
  • , Jian Zhang

Research output: Contribution to journalArticlepeer-review

Abstract

Akt-1 and Akt-2 are the major isoforms of the serine/threonine Akt family that play a key role in controlling immune responses. However, the involvement of Akt-1 and Akt-2 isoforms in antifungal innate immunity is completely unknown. In this study, we show that Akt2-/-, but not Akt1-/-, mice are protected from lethal Candida albicans infection. Loss of Akt-2 facilitates the recruitment of neutrophils and macrophages to the spleen and increases reactive oxygen species expression in these cells. Treating C57BL/6 mice with a specific inhibitor for Akt-2, but not Akt-1, provides protection from lethal C. albicans infection. Our data demonstrate that Akt-2 inhibits antifungal innate immunity by hampering neutrophil and macrophage recruitment to spleens and suppressing oxidative burst, myeloperoxidase activity, and NETosis. We thus describe a novel role for Akt-2 in the regulation of antifungal innate immunity and unveil Akt-2 as a potential target for the treatment of fungal sepsis.
Original languageEnglish
Pages (from-to)991-1000
Number of pages10
JournalJournal of Immunology
Volume209
Issue number5
DOIs
Publication statusPublished - Sept 2022

Fingerprint

Dive into the research topics of 'Akt-2 Is a Potential Therapeutic Target for Disseminated Candidiasis'. Together they form a unique fingerprint.

Cite this